Most providers in this market are two years old. WeightWatchers has been running behavioural weight management since 1963, which is the entire argument for choosing it.
Its clinic membership is $74 a month on a twelve-month plan or $84 on a six-month plan, after an introductory period. Medication is billed separately, and the formulary is branded — Wegovy, Zepbound, Saxenda, plus metformin and naltrexone/bupropion for people who are not candidates for a GLP-1.
That last detail matters more than it looks. Carrying non-GLP-1 options means the programme can treat people the drugs are not appropriate for, rather than routing everyone to the same injection.
The comparison that actually applies
Not against CoreAge Rx at $79 or Mochi at $139 — those are medication prices and this is a programme fee. The relevant comparison is Noom Med at $179 a month, which bundles medication into the programme price but delivers it as a microdose.
WeightWatchers prescribes branded products at standard doses with medication billed separately; Noom bundles a microdose. If you want a behavioural programme alongside doses the trials actually studied, WeightWatchers is the one that does it.
The commitment
The $74 rate requires a twelve-month plan and $84 requires six. For a behavioural programme that is a more defensible commitment than it would be for a vial subscription — behaviour change is a long project and short-horizon pricing works against it — but it is still a commitment made before you know whether the medication suits you.
Your muscle-protection numbers
Weight lost on a GLP-1 is not all fat. Protein intake and resistance training are the two levers with the best evidence behind them. Set your weight to see the targets.
Daily protein target
120–200 g
Roughly 30 g at each of four eating occasions gets you to the bottom of that range.
Resistance training
2–3 ×/week
Full-body sessions covering legs, push and pull. Loaded movement is the signal that tells your body to keep the muscle.
General nutrition and activity information, not medical advice. Protein targets can be inappropriate in kidney disease and some other conditions — check with your clinician before changing your intake.
What Wegovy is, and what it costs at source
Wegovy is semaglutide, approved by FDA for chronic weight management. In its registrational programme adults reached a 2.4 mg weekly maintenance dose and lost an average of about 15% of body weight over 68 weeks, with roughly one in three achieving 20%. It is also approved to reduce cardiovascular risk in adults with established cardiovascular disease, which is the narrow route by which Medicare can cover it at all.
The number that should anchor every Wegovy quote is Novo Nordisk's own self-pay price. NovoCare publishes tablets at $149 a month, the 0.25 mg and 0.5 mg injections at $199, the 1 mg to 2.4 mg maintenance doses at $349, and the 7.2 mg at $399 — with no membership and no prior authorisation.
Before you buy branded from a reseller
- Check the manufacturer's own price first — NovoCare for Wegovy, LillyDirect for Zepbound. Resale prices range across an order of magnitude.
- Establish whether a membership or programme fee is charged on top of the medication.
- Ask what the price is at your expected maintenance dose, since branded pricing usually rises with dose.
- If you have type 2 diabetes, ask about Ozempic or Mounjaro through insurance before paying cash for anything.
- Confirm whether the provider will submit a prior authorisation, and what happens if it is denied.